Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer
ESMO Open,
Год журнала:
2024,
Номер
9(7), С. 103619 - 103619
Опубликована: Июнь 28, 2024
The
characterization
and
comparison
of
gene
expression
intrinsic
subtype
(IS)
changes
induced
by
neoadjuvant
chemotherapy
(NACT)
endocrine
therapy
in
hormone
receptor-positive
(HR+)/human
epidermal
growth
factor
receptor
2
(HER2)-low
versus
HR+/HER2-0
breast
cancer
(BC)
has
not
been
conducted
so
far.
Most
evidence
on
the
association
HER2
status
with
pathologic
responses
prognosis
HR+/HER2-negative
BC
is
controversial
restricted
to
NACT-treated
disease.
Similarly,
a
temporal
heterogeneity
described
only
NACT.
Язык: Английский
Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review
The Breast,
Год журнала:
2025,
Номер
unknown, С. 104465 - 104465
Опубликована: Апрель 1, 2025
We
present
the
first
documented
oncologic
case
of
a
type
I
Kounis
syndrome
(KS)
following
paclitaxel
administration,
in
very
young
patient
with
HER2-positive(+)
early-stage
breast
cancer
(BC).
KS
is
relatively
rare
acute
coronary
triggered
by
anaphylactic
or
hypersensitivity
reactions,
which
there
limited
awareness
among
healthcare
providers.
It
subdivided
four
subtypes
depending
on
cardiac
artery
medical
history.
While
no
established
management
guidelines
exist,
its
treatment
requires
addressing
severe
infusion
reactions
while
ensuring
proper
myocardial
perfusion.
hereby
illustrate
successful
and
report
how
tumor
genomics
through
novel
HER2DX
assay
helped
re-defining
entire
neo/adjuvant
strategy.
integrates
size
nodal
involvement
27
genes'
expression
data
tracking
biological
BC-related
immunologic
signatures
so
to
estimate
prognostic
predictive
score.
This
demonstrates
clinical
genomic
can
be
effectively
integrated
optimize
therapeutic
decisions
HER2+
BC,
offering
model
for
personalized
care
also
atypical
complex
cases.
Язык: Английский
Hormone receptor-positive early breast cancer in young women: A comprehensive review
Cancer Treatment Reviews,
Год журнала:
2024,
Номер
129, С. 102804 - 102804
Опубликована: Июль 14, 2024
Язык: Английский
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis
Cancer Treatment Reviews,
Год журнала:
2024,
Номер
132, С. 102865 - 102865
Опубликована: Дек. 19, 2024
Язык: Английский
From Text to Insight: A Natural Language Processing-Based Analysis of Burst and Research Trends in HER2-low Breast Cancer Patients
Ageing Research Reviews,
Год журнала:
2025,
Номер
106, С. 102692 - 102692
Опубликована: Фев. 22, 2025
With
the
intensification
of
population
aging,
proportion
elderly
breast
cancer
patients
is
continuously
increasing,
among
which
those
with
low
HER2
expression
account
for
approximately
45
%-55
%
all
cases
within
traditional
HER2-negative
cancer.
Concurrently,
significant
therapeutic
effect
T-DXd
on
HER2-low
tumors
has
brought
this
group
into
public
spotlight.
Since
clinical
approval
in
2019,
there
been
a
vertical
surge
volume
publications
domain.
We
analyzed
512
articles
from
Web
Science
Core
Collection
using
bibliometrics,
topic
modeling,
and
knowledge
graph
techniques
to
summarize
current
state
trends
research
Research
efforts
are
particularly
concentrated
United
States
China.
Our
analysis
revealed
six
main
directions:
detection,
omics
biomarkers,
basic
translational
research,
neoadjuvant
therapy
prognosis,
progress
ADC
drugs
trials.
To
enhance
efficacy
safety
antibodydrug
conjugates
(ADCs),
researchers
actively
exploring
potential
drug
candidates
other
than
T-DXd,
numerous
emerging
practice
By
incorporating
treatment
strategies
such
as
immunotherapy
employing
circulating
tumor
cell
(CTC)
detection
techniques,
made
toward
improving
prognosis
expression.
believe
that
these
hold
promise
compelling
evidence
may
constitute
distinct
independent
subtype.
Язык: Английский
Risk of second primary cancer in young breast cancer survivors: an important yet overlooked issue
Therapeutic Advances in Medical Oncology,
Год журнала:
2025,
Номер
17
Опубликована: Янв. 1, 2025
Currently,
female
breast
cancer
(BC)
represents
the
highest
incidence
of
globally.
This
trend
has
raised
significant
attention
regarding
young
women
(BCYW).
With
advancements
in
treatment
technology,
BCYW
survivors
are
living
longer;
however,
risk
developing
or
succumbing
to
a
second
primary
(SPC)
greatly
increased.
In
addition,
several
factors,
including
age,
menstrual
cycle,
hormonal
changes,
obesity,
pregnancy,
and
breastfeeding,
interact
influence
development
SPC
make
its
more
difficult.
study
investigates
relationship
between
SPC,
focusing
on
morbidity
trends,
pathological
genomics,
recurrence
rates,
survival
times,
modalities,
physiological
fertility.
Most
involve
BRCA
pathogenic
variants
fall
under
triple-negative
human
epidermal
growth
factor
receptor
2-overexpressing
subtypes,
increasing
SPC.
While
there
regional
variations
time
following
diagnosis
an
long-term
outcomes
remain
unfavorable.
choice
for
prolonged
cumulative
toxic
effect.
The
combination
endocrine
therapy
chemotherapy
is
effective
treating
BC,
but
it
simultaneously
increases
specifically
endometrial
cancer.
Furthermore,
radiotherapy
associated
with
heightened
contralateral
BC
lung
We
aim
address
existing
gaps
literature
enhance
awareness
risks
BCYW,
thereby
offering
valuable
insights
clinical
treatment.
Язык: Английский
Clinical Impact and Genomic Features of Human Epidermal Growth Factor Receptor 2–Low Tumors in BRCA1/2 -Mutated Triple-Negative Breast Cancer
JCO Precision Oncology,
Год журнала:
2025,
Номер
9
Опубликована: Март 1, 2025
PURPOSE
Data
about
the
clinical
impact
of
human
epidermal
growth
factor
receptor
2
(HER2)–low
expression
in
BRCA1/2
-mutated
breast
cancer
(BC)
are
limited.
This
study
aimed
to
clarify
relevance
HER2-low
operable
BC.
MATERIALS
AND
METHODS
A
total
495
HER2-negative
BC
with
germline
pathogenic
variants
treated
at
our
institute
between
October
2003
and
September
2020
were
included.
was
defined
as
immunohistochemistry
(IHC)
1+
or
2+/fluorescence
situ
hybridization–negative,
while
HER2-zero
IHC
0.
Tumor
DNA
from
25
triple-negative
BCs
(TNBCs)
subjected
whole-exome
sequencing.
RESULTS
Among
186
BRCA1
carriers,
38.8%
TNBC
(n
=
121)
52.3%
hormone
receptor–positive/HER2-negative
65)
exhibited
tumors
subgroup;
among
309
BRCA2
44.9%
49)
68.1%
260)
subgroup.
After
a
median
follow-up
10.9
years
(range,
1.23-19.8
years),
TNBC,
significantly
associated
better
recurrence-free
survival
(RFS;
10-year
RFS:
90.3%
v
75.1%;
P
.015),
distant
(DRFS;
DRFS:
92.4%
76.5%;
.010),
overall
(OS;
OS:
94.6%
77.4%;
.007)
than
tumors.
However,
not
observed
either
BRCA1-
Notably,
mutated
showed
higher
homologous
recombination
deficiency
scores
those
CONCLUSION
patients
have
favorable
survival,
highlighting
possibility
stratifying
these
into
two
subgroups
on
basis
status.
Язык: Английский
Comprehensive analysis of HER2 Low Breast Cancer Response to Neoadjuvant Chemotherapy, a Retrospective Cohort Study
Clinical Breast Cancer,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Язык: Английский
Clinicopathological characteristics and long-term prognosis of triple-negative breast cancer patients with HER2-Low expression: a retrospective propensity score-matched cohort study
Journal of Cancer Research and Clinical Oncology,
Год журнала:
2024,
Номер
151(1)
Опубликована: Дек. 27, 2024
The
objective
of
the
current
research
was
to
assess
clinicopathological
characteristics
and
long-term
prognosis
triple-negative
breast
cancer
(TNBC)
patients
with
human
epidermal
growth
factor
receptor
2
(HER2)-low
status
following
surgery.
A
total
202
TNBC
treated
at
Qingdao
Central
Hospital
from
January
2010
December
2019
were
included,
comprising
71
HER2-low
131
HER2-zero
patients.
Propensity
score
matching
(PSM)
applied
minimize
differences
between
cohorts.
had
lower
histological
grade,
Ki-67
expression
levels,
a
higher
prevalence
hypertension
compared
Before
after
PSM,
group
consistently
exhibited
recurrence
rate
longer
RFS
validated
as
an
independent
low-risk
for
both
pre-PSM
(HR
0.354,
95%
CI
0.178–0.706,
p
=
0.003)
post-PSM
0.405,
0.185–0.886,
0.024).
No
statistically
significant
in
mortality
OS
observed,
before
PSM.
show
differences.
Compared
HER2-zero,
is
linked
better
serves
Язык: Английский